Human Growth Hormone (HGH, Somatotropin)

1. Overview

Human growth hormone (hGH), also known as somatotropin, is a 191-amino acid, 22 kDa single-chain polypeptide hormone synthesized and secreted by somatotroph cells of the anterior pituitary gland. It is the most abundant pituitary hormone, with approximately 5 to 10 mg stored in the adult pituitary at any given time. The mature protein adopts a four-helix bundle topology stabilized by two intramolecular disulfide bonds (Cys53-Cys165 and Cys182-Cys189) and is encoded by the GH1 gene on chromosome 17q23.3 [1].

Growth hormone secretion follows a pulsatile pattern regulated by the hypothalamic hormones growth hormone-releasing hormone (GHRH, stimulatory) and somatostatin (inhibitory), with the ghrelin/GH secretagogue receptor system providing a third regulatory input. The largest secretory pulse occurs during the first period of slow-wave (stage III-IV) sleep, and total daily GH output peaks during puberty at approximately 700 mcg/day before declining progressively with age at a rate of roughly 14% per decade after age 30 [4][6].

The primary structure of hGH was first determined by Li and Dixon in 1971 [1]. Recombinant human growth hormone (rhGH, somatropin) became available in 1985 following the landmark expression of the hGH gene in Escherichia coli by Goeddel et al. in 1979 [5], replacing cadaveric pituitary-derived GH (somatrem) that had been associated with Creutzfeldt-Jakob disease transmission. Today, multiple rhGH products are FDA-approved -- including Genotropin (Pfizer), Humatrope (Lilly), Norditropin (Novo Nordisk), Saizen (Merck Serono), Nutropin (Genentech), Omnitrope (Sandoz), and Zomacton (Ferring) -- making it one of the most widely prescribed biologic therapeutics worldwide [17].

Type

Endogenous pituitary polypeptide hormone

Amino Acids

191 residues, single-chain, four-helix bundle

Molecular Weight

22,124 Da (22 kDa)

Gene

GH1 (chromosome 17q23.3)

Receptor

Growth Hormone Receptor (GHR); JAK2/STAT5 signaling

Half-life

3.4-4.2 hours (subcutaneous); 20-30 minutes (intravenous)

Secretion Pattern

Pulsatile; largest pulse during slow-wave sleep

FDA-Approved Brands

Genotropin, Humatrope, Norditropin, Saizen, Nutropin, Omnitrope, Zomacton

WADA Status

Prohibited at all times (S2: Peptide Hormones, Growth Factors)

2. Molecular Structure and Secretion

2.1 Protein Architecture

The 22 kDa hGH molecule consists of 191 amino acids arranged in a four-helix bundle characteristic of the class I cytokine superfamily. The four alpha-helices (designated A, B, C, and D) are connected by loop regions, with the two disulfide bonds (Cys53-Cys165 forming a large loop, Cys182-Cys189 forming a small C-terminal loop) essential for proper folding and receptor binding [1][2]. The crystal structure of the GH-GHR complex, solved by de Vos, Ultsch, and Kossiakoff in 1992 at 2.8 angstrom resolution, revealed that a single hGH molecule binds two GHR molecules sequentially through two distinct binding sites (Site 1 and Site 2) on opposite faces of the hormone, inducing receptor dimerization as the initiating event in signal transduction [2].

Alternative splicing of the GH1 gene produces a minor 20 kDa variant (lacking residues 32-46) that constitutes approximately 5-10% of circulating GH. This variant retains growth-promoting and lipolytic activity but has reduced diabetogenic effects compared to the dominant 22 kDa form.

2.2 Secretory Regulation

GH secretion is governed by a complex neuroendocrine network:

• GHRH (stimulatory): Released from arcuate nucleus neurons, binds GHRH receptor on somatotrophs to stimulate GH synthesis and release via cAMP/PKA pathway
• Somatostatin (inhibitory): Released from periventricular nucleus neurons, binds SSTR2/SSTR5 on somatotrophs to suppress GH release without affecting synthesis
• Ghrelin (stimulatory): Stomach-derived peptide that binds GHS-R1a on somatotrophs and hypothalamic neurons, providing a peripheral metabolic signal that amplifies GH pulses
• IGF-1 (negative feedback): Circulating IGF-1 produced by the liver in response to GH acts on both the hypothalamus (stimulating somatostatin) and the pituitary (directly suppressing GH release) to complete the feedback loop

Secretion is enhanced by sleep, exercise, hypoglycemia, amino acids (particularly arginine), and sex steroids (estrogen and testosterone), while it is suppressed by hyperglycemia, free fatty acids, glucocorticoids, and obesity.

3. Mechanism of Action

3.1 GHR/JAK2/STAT5 Signaling

Growth hormone exerts its effects by binding the transmembrane growth hormone receptor (GHR), a member of the class I cytokine receptor family. The signaling cascade proceeds as follows [2][3][4]:

1. hGH binds the first GHR molecule through its high-affinity Site 1, forming a 1:1 complex
2. The hGH-GHR complex recruits a second GHR molecule through the lower-affinity Site 2, inducing receptor dimerization
3. Receptor dimerization activates the constitutively associated tyrosine kinase Janus kinase 2 (JAK2) through trans-phosphorylation [3]
4. Activated JAK2 phosphorylates tyrosine residues on the GHR intracellular domain, creating docking sites for signaling molecules
5. Signal transducer and activator of transcription 5b (STAT5b) is recruited, phosphorylated by JAK2, dimerizes, and translocates to the nucleus to regulate target gene transcription [4]
6. STAT5b directly activates transcription of the IGF-1 gene in hepatocytes and other tissues

Additional signaling pathways activated by GHR include the MAPK/ERK pathway (mediating cell proliferation), PI3K/Akt pathway (mediating metabolic effects and cell survival), and STAT1/STAT3 pathways.

3.2 Direct and Indirect Actions

Growth hormone exerts its biological effects through two complementary mechanisms:

Direct actions (GH acting directly on target tissues):

• Lipolysis: GH directly stimulates triglyceride hydrolysis in adipocytes through hormone-sensitive lipase activation
• Diabetogenic effects: GH antagonizes insulin action in muscle and adipose tissue, promoting insulin resistance
• Hepatic glucose output: GH stimulates gluconeogenesis
• Sodium and water retention: GH promotes renal sodium reabsorption

Indirect actions (mediated by IGF-1):

• Linear growth: IGF-1 produced locally in growth plate chondrocytes (paracrine) and systemically by the liver (endocrine) drives longitudinal bone growth
• Muscle protein synthesis: IGF-1 activates the PI3K/Akt/mTOR pathway in skeletal muscle
• Organ growth: IGF-1 promotes cell proliferation and differentiation in multiple tissues
• Bone mineralization: IGF-1 stimulates osteoblast activity

The "dual effector theory" and the "somatomedin hypothesis" describe this division of labor, with GH primarily responsible for metabolic effects and tissue differentiation, while IGF-1 mediates the growth-promoting and anabolic actions [4].

4. Approved Clinical Indications

Recombinant hGH (somatropin) is FDA-approved for the following indications [6][7][8][9][17][18][19]:

4.1 Pediatric Indications

Growth Hormone Deficiency (GHD): The primary indication. Children with confirmed GHD (based on provocative GH testing showing peak GH below 10 ng/mL in most protocols, combined with clinical criteria including growth velocity below the 25th percentile and delayed bone age) receive daily subcutaneous rhGH at doses of 0.025-0.050 mg/kg/day. Treatment typically continues until growth plate closure or until the patient achieves satisfactory adult height. The GH Research Society 2000 consensus established standardized diagnostic criteria that remain foundational [6].

Turner Syndrome: Girls with 45,X or other X-chromosome abnormalities experience growth failure due to SHOX gene haploinsufficiency rather than GH deficiency per se. rhGH at higher doses (0.045-0.067 mg/kg/day) increases adult height by an average of 5-8 cm. Davenport et al. demonstrated that treatment initiated before age 4 produced superior height normalization [8].

Prader-Willi Syndrome (PWS): rhGH improves growth, body composition (increasing lean mass, decreasing fat mass), muscle tone, and physical function in PWS. Dosing is typically 0.035 mg/kg/day. Safety monitoring is essential due to reported cases of sudden death during early treatment in PWS patients with severe obesity, sleep apnea, or respiratory infection [19].

Idiopathic Short Stature (ISS): Children with height below -2.25 SDS without identifiable cause may receive rhGH at doses up to 0.053 mg/kg/day. Wit et al. demonstrated a dose-dependent increase in adult height, with higher doses producing approximately 5-7 cm of additional height gain [7]. This indication remains controversial, as it medicalizes the lower end of normal height distribution.

Small for Gestational Age (SGA): Children born SGA who fail to demonstrate catch-up growth by age 2-4 years may receive rhGH treatment.

Short Stature Homeobox-containing Gene (SHOX) Deficiency: rhGH is indicated for growth failure associated with SHOX gene mutations.

Chronic Renal Insufficiency: Children with growth failure secondary to chronic kidney disease.

Noonan Syndrome: FDA-approved for growth failure associated with Noonan syndrome.

4.2 Adult Indications

Adult Growth Hormone Deficiency (AGHD): Adults with confirmed GHD -- either childhood-onset (retested after growth completion) or adult-onset (due to pituitary tumors, surgery, radiation, or traumatic brain injury) -- may receive replacement therapy. The Endocrine Society 2011 guidelines recommend starting at low doses (0.15-0.30 mg/day) and titrating based on clinical response and IGF-1 levels, with typical maintenance doses of 0.4-0.8 mg/day [18]. Women generally require higher doses than men, particularly those receiving oral estrogen replacement. KIMS database analyses involving over 10,000 AGHD patients demonstrated sustained improvements in body composition, lipid profiles, bone mineral density, and quality of life over 5-10 years of follow-up [9].

Short Bowel Syndrome: FDA-approved for short bowel syndrome in adults receiving specialized nutritional support (Zorbtive brand).

HIV-associated Wasting/Lipodystrophy: Tesamorelin (a GHRH analog) is the preferred agent, but rhGH has been used for HIV-associated wasting and adipose redistribution.

5. Researched Applications

5.1 Anti-Aging

Evidence level: Weak; not supported by clinical evidence

Interest in GH as an anti-aging therapy surged following the 1990 publication by Rudman et al. in the New England Journal of Medicine, reporting that six months of rhGH administration to healthy men over 60 increased lean body mass by 8.8% and decreased adipose tissue by 14.4%. However, this small uncontrolled study (n=12 treated, 9 controls) did not assess functional outcomes and reported significant adverse effects.

Subsequent systematic reviews have consistently found that while GH modestly increases lean body mass (approximately 2 kg) and reduces fat mass (approximately 0.4 kg) in healthy elderly individuals, it does not improve muscle strength, aerobic capacity, bone density, cognitive function, or any validated measure of functional performance [10][11]. The Stanford University meta-analysis by Liu et al. (2007) analyzing 31 studies concluded that adverse effects -- including soft tissue edema, arthralgias, carpal tunnel syndrome, gynecomastia, and glucose intolerance -- were common, occurring in up to 24-46% of GH-treated subjects versus 0-5% of controls [10]. The authors explicitly concluded that GH cannot be recommended as an anti-aging therapy.

5.2 Athletic Performance Enhancement

Evidence level: Moderate evidence of no benefit in healthy athletes

Despite widespread use in professional and amateur sports, evidence does not support performance-enhancing effects of GH in trained athletes. Holt and Sonksen (2008) reviewed the evidence and concluded that while GH increases lean body mass, the gained mass appears to consist primarily of water and connective tissue rather than contractile muscle protein [15]. Controlled studies in young healthy adults showed no improvement in strength, power, or endurance capacity with GH administration [15][16].

GH is prohibited at all times by WADA under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Detection relies on two complementary approaches: the isoform ratio test (detecting the shift toward recombinant 22 kDa GH at the expense of endogenous isoforms) and the biomarker approach (measuring GH-dependent markers IGF-1 and P-III-NP/procollagen type III N-terminal peptide) [16].

6. Clinical Evidence Summary

7. Dosing in Research

The following table summarizes FDA-approved dosing protocols and doses used in published research. These represent evidence-based prescribing information for approved indications.

8. Safety and Side Effects

8.1 Common Adverse Effects

The most frequently reported side effects of rhGH therapy include [10][13][14]:

• Fluid retention: Peripheral edema, arthralgias, myalgias, and paresthesias occur in 10-30% of adults initiating therapy, typically dose-related and resolving with dose reduction
• Carpal tunnel syndrome: Occurs in 2-5% of adult patients, more common at higher doses
• Insulin resistance: GH directly antagonizes insulin signaling; fasting glucose and HbA1c should be monitored. Progression to frank diabetes is uncommon with appropriate dosing
• Gynecomastia: Reported primarily in older men
• Headache: Common in pediatric patients, particularly at treatment initiation
• Injection site reactions: Localized pain, redness, or lipodystrophy

8.2 Serious Adverse Effects and Long-Term Safety

Cancer Risk: The relationship between GH/IGF-1 and cancer remains an area of active investigation. The SAGhE European Cohort Study (2017) following over 10,000 childhood GH recipients found no overall increase in cancer mortality but identified a potential dose-dependent signal for bone and bladder cancer that requires continued surveillance [12]. In adults with GHD without prior cancer history, large registry studies have not demonstrated significantly increased cancer incidence [14]. However, GH is contraindicated in the presence of active malignancy due to the theoretical risk of promoting tumor growth through IGF-1-mediated cell proliferation. Cancer survivors should be monitored carefully, as some studies suggest modestly increased risk of second neoplasms.

Intracranial Hypertension (Pseudotumor Cerebri): Rare but recognized complication, primarily in pediatric patients. Presents with headache, visual changes, and papilledema. Usually resolves with GH discontinuation and may not recur upon rechallenge at lower doses [13].

Slipped Capital Femoral Epiphysis (SCFE): Children receiving GH therapy have an increased risk of SCFE, likely due to accelerated growth. Any child on GH reporting hip or knee pain should be evaluated immediately [13].

Prader-Willi Syndrome Safety: Rare cases of sudden death have been reported in PWS patients during early GH treatment, particularly those with severe obesity (BMI greater than 40), undiagnosed or untreated sleep apnea, or active upper respiratory infection. Current guidelines mandate sleep apnea screening before and during therapy, with contraindication in patients with severe respiratory impairment [19].

Scoliosis Progression: GH treatment may accelerate progression of pre-existing scoliosis due to rapid growth. Monitoring with periodic spinal examination is recommended.

8.3 Long-Term Surveillance

Long-term safety data from the KIMS database and other registries spanning over 15 years of follow-up in adults with GHD support a favorable benefit-risk profile when GH is used at physiological replacement doses [14]. The key principle is to dose to normalize IGF-1 levels within the age-appropriate reference range (typically targeting the mid-normal range) rather than to supraphysiological levels.

9. Long-Acting Formulations

A major advance in GH therapeutics has been the development of long-acting formulations to replace the burden of daily injections [20]:

• Somapacitan (Sogroya): FDA-approved in 2020 for adult GHD. Once-weekly subcutaneous injection. Albumin-binding GH derivative with sustained pharmacokinetics.
• Lonapegsomatropin (Skytrofa): FDA-approved in 2021 for pediatric GHD. Once-weekly injection. TransCon (transient conjugation) technology with a PEG carrier that releases native GH.
• Somatrogon (Ngenla): FDA-approved in 2022 for pediatric GHD. Once-weekly injection. Fusion protein of GH with CTP (C-terminal peptide of hCG beta subunit). The REAL 3 Phase 3 trial demonstrated non-inferiority to daily somatropin for height velocity (10.1 vs 9.8 cm/year).

These weekly formulations have comparable efficacy and safety to daily GH and are expected to improve adherence, which is a significant barrier in long-term GH therapy.

2025-2026 Regulatory Expansions

• Lonapegsomatropin (Skytrofa) -- Adult GHD Approval (July 2025): The FDA approved Skytrofa for the replacement of endogenous GH in adults with GHD, based on the foresiGHt Phase 3 trial (n=259). Lonapegsomatropin significantly reduced trunk percent fat (-1.7% vs +0.4% placebo; P <0.0001), increased lean body mass (+1.6 kg vs -0.1 kg), and normalized IGF-1 SDS to 1.4 versus -2.6 with placebo at 38 weeks. Safety was comparable to daily somatropin. This makes Skytrofa the first once-weekly GH approved for both pediatric and adult GHD.
• Somapacitan (Sogroya) -- Pediatric Expansion (February 2026): Sogroya received FDA approval for three additional pediatric indications: idiopathic short stature (ISS), short stature born small for gestational age (SGA) without catch-up growth by age 2, and growth failure associated with Noonan syndrome (NS), in children aged 2.5 years and older. In ISS, Sogroya demonstrated non-inferiority to daily somatropin (10.2 vs 10.5 cm/year). Somapacitan now holds the broadest range of approved indications among long-acting growth hormones in the United States.
• Tesamorelin F8 (EGRIFTA WR) -- New Formulation (March 2025): The FDA approved a new weekly-reconstitution formulation of tesamorelin (EGRIFTA WR) for HIV-associated lipodystrophy, requiring less than half the injection volume of its predecessor and enabling weekly rather than daily reconstitution, improving treatment adherence.

10. Illicit Use and Regulatory Considerations

10.1 Anti-Aging Clinics

The distribution of hGH for anti-aging or body composition enhancement to otherwise healthy adults is illegal under U.S. federal law. The 1990 Anabolic Steroids Control Act and the 2007 amendment to Section 303(e) of the Federal Food, Drug, and Cosmetic Act specifically criminalize the distribution of hGH for any purpose other than FDA-approved indications. Despite this, a significant gray market exists through anti-aging clinics, online pharmacies, and compounding pharmacies. The Endocrine Society has explicitly stated that GH therapy should not be prescribed for anti-aging purposes [18].

10.2 Sports Doping

GH abuse in sports has been documented since at least the 1980s. Detection has been challenging because recombinant hGH is structurally identical to endogenous GH. WADA-accredited laboratories employ two testing strategies: the isoform differential immunoassay (detecting suppression of non-22 kDa isoforms following exogenous 22 kDa GH injection, with a detection window of 12-24 hours) and the GH biomarkers test (measuring IGF-1 and P-III-NP, with a detection window of approximately 2-3 weeks) [16]. The first confirmed positive test using the isoform method was at the 2010 Tour de France (cyclist Thomas Flieger), followed by British rugby league player Terry Newton in 2010.

11. Pharmacokinetics

Recombinant hGH (somatropin) is a 22 kDa single-chain polypeptide administered by subcutaneous injection due to negligible oral bioavailability (proteolytic degradation in the GI tract) [6][17].

Absorption. After subcutaneous injection, hGH is absorbed from the injection depot with Tmax of approximately 3-5 hours. Bioavailability is approximately 70-80% (subcutaneous) compared to intravenous administration. Absorption follows first-order kinetics and is not significantly affected by injection site (abdomen, thigh, deltoid) [17].

Distribution. Volume of distribution at steady state is approximately 0.07-0.10 L/kg (approximately 5-7 L in adults). Approximately 60% of circulating GH is bound to GH binding protein (GHBP, the cleaved extracellular domain of the GH receptor), which modulates bioavailability and extends half-life. The remaining 40% is in the free form available for receptor binding [2].

Metabolism. Metabolized primarily by the liver and kidneys through proteolytic degradation. Hepatic metabolism accounts for the majority of clearance. The kidneys contribute through glomerular filtration and tubular catabolism. No active metabolites [17].

Elimination. Terminal half-life is approximately 3.4-4.2 hours (subcutaneous) versus 20-30 minutes (intravenous). The longer subcutaneous half-life reflects rate-limited absorption from the depot (flip-flop kinetics). Clearance is approximately 2.5-3.0 mL/min/kg. The relatively short half-life necessitates daily injections, which has driven development of long-acting formulations [17][20].

Pulsatile physiology vs exogenous PK. Endogenous GH is secreted in discrete pulses (largest during slow-wave sleep) with inter-pulse troughs near zero, producing a highly pulsatile profile. Daily subcutaneous injection creates a non-physiological sustained elevation for approximately 12-18 hours. Whether pulsatile delivery would improve outcomes remains debated, but current daily dosing regimens have demonstrated consistent efficacy [6].

Long-acting formulations PK. Weekly formulations achieve sustained GH exposure: somapacitan (albumin-binding GH derivative, t1/2 approximately 160 h), lonapegsomatropin (TransCon technology releasing native GH, effective t1/2 approximately 25 h with sustained release over 7 days), somatrogon (CTP fusion, t1/2 approximately 28 h) [20].

Special populations. Children have higher weight-adjusted clearance than adults, requiring higher mg/kg dosing. Women generally require higher doses than men, especially those on oral estrogen (which suppresses hepatic IGF-1 production). Renal and hepatic impairment reduce GH clearance but dose adjustment is based on IGF-1 monitoring rather than formulaic reduction.

12. Dose-Response Relationship

Pediatric GHD growth velocity dose-response. Dose-dependent increases in growth velocity are well-established. Standard replacement doses (0.025-0.050 mg/kg/day) typically produce first-year height velocities of 8-12 cm/year, declining in subsequent years. Wit et al. (2005) demonstrated in children with idiopathic short stature that higher doses (0.37 mg/kg/week) produced approximately 7.2 cm of adult height gain versus 5.4 cm with lower doses (0.22 mg/kg/week), confirming a dose-dependent final height effect [7].

Turner syndrome. Higher doses (0.045-0.067 mg/kg/day) are required due to the non-GH-deficient mechanism of growth failure (SHOX haploinsufficiency). Average adult height gain is 5-8 cm above untreated predictions, with dose-dependent response [8].

Adult GHD IGF-1 dose-response. In adults, dosing is titrated to normalize IGF-1 levels within the age-appropriate reference range (targeting mid-normal). Starting doses are low (0.15-0.30 mg/day) to minimize fluid retention and are uptitrated by 0.1-0.2 mg increments every 4-6 weeks. Women generally require higher doses than men (0.6-1.0 mg/day vs 0.4-0.6 mg/day), partly because oral estrogen suppresses hepatic IGF-1 production via first-pass effect [9][18].

Body composition dose-response. In healthy elderly, the Liu meta-analysis showed that GH increased lean mass by approximately 2.1 kg and decreased fat mass by approximately 0.4 kg, but these changes did not translate to improved strength, aerobic capacity, or functional performance at any dose studied [10][11].

Anti-aging/supraphysiological dose-response. At supraphysiological doses used in illicit contexts (typically 2-4 IU/day, far exceeding replacement), adverse effects (fluid retention, carpal tunnel, insulin resistance) increase steeply without evidence of functional benefit. The dose-adverse effect relationship is non-linear, with adverse effects escalating disproportionately at higher doses [10][15].

13. Comparative Effectiveness

Daily somatropin vs weekly somapacitan (Sogroya). Somapacitan achieved comparable improvements in body composition, quality of life, and IGF-1 normalization in adult GHD with the convenience of once-weekly dosing. FDA-approved 2020 for adult GHD.

Daily somatropin vs weekly lonapegsomatropin (Skytrofa). The heiGHt Phase 3 trial demonstrated non-inferiority for annualized height velocity in pediatric GHD. TransCon technology releases native (unmodified) GH, an advantage for safety extrapolation. FDA-approved 2021 for pediatric GHD.

Daily somatropin vs weekly somatrogon (Ngenla). REAL 3 Phase 3 trial demonstrated non-inferiority (10.1 vs 9.8 cm/year height velocity at 12 months) with comparable safety. CTP fusion protein approach. FDA-approved 2022 for pediatric GHD [REAL 3 study].

GH replacement vs GH secretagogues. GH secretagogues (sermorelin, CJC-1295, ipamorelin, MK-677) stimulate endogenous GH release and produce a more physiological pulsatile pattern but achieve lower and less consistent IGF-1 elevation than exogenous GH replacement. They are generally less effective for severe GHD but may have a role in mild/partial GHD or as adjunctive therapy [17].

rhGH vs GH for anti-aging. The systematic evidence (Liu et al., 2007; Rubeck et al., 2009) conclusively demonstrates that GH in healthy elderly increases lean mass without improving strength, function, or validated endpoints, while producing significant adverse effects in 24-46% of subjects. No anti-aging benefit has been demonstrated in any controlled study [10][11].

14. Enhanced Safety Profile

Fluid retention management. Edema, arthralgias, myalgias, and paresthesias occur in 10-30% of adults initiating therapy. These are dose-related and typically resolve within weeks of dose reduction. Starting at low doses and titrating slowly is the primary prevention strategy [10][13].

Glucose metabolism. GH directly antagonizes insulin action, increasing fasting glucose, insulin resistance, and HbA1c. In properly dosed replacement, progression to overt diabetes is uncommon, but fasting glucose and HbA1c should be monitored at initiation, at 3 months, and annually. Patients with pre-existing insulin resistance or prediabetes require closer monitoring [13][14].

Cancer surveillance. The SAGhE European Cohort (greater than 10,000 childhood GH recipients) found no overall increased cancer mortality. Possible dose-dependent signals for bone and bladder cancer require continued surveillance. GH is contraindicated with active malignancy. Cancer survivors should have completed treatment and be in remission for an appropriate observation period before GH initiation. IGF-1 levels should be monitored and maintained within the mid-normal range [12][14].

Intracranial hypertension. Rare in pediatric patients. Presents with headache, visual changes, papilledema. Usually resolves with GH discontinuation and may not recur at lower doses [13].

Prader-Willi syndrome safety. Mandatory sleep apnea screening before and during therapy. Contraindicated in severe obesity (BMI greater than 40), severe upper airway obstruction, or active respiratory infection. Reported sudden deaths linked to undiagnosed/untreated sleep apnea [19].

Scoliosis. May accelerate progression of pre-existing scoliosis through rapid growth. Periodic spinal examination recommended in all pediatric patients on GH therapy [13].

Slipped capital femoral epiphysis (SCFE). Increased risk in GH-treated children. Hip or knee pain requires immediate orthopedic evaluation [13].

Long-term safety. KIMS database (greater than 10,000 adults, up to 15 years follow-up) supports a favorable benefit-risk profile when dosing targets mid-normal IGF-1 levels. Supraphysiological IGF-1 levels are associated with increased adverse effects and theoretical oncogenic risk and should be avoided [9][14].

Drug interactions. GH may increase CYP3A4-mediated clearance of drugs metabolized by this pathway (cortisone, corticosteroids, sex steroids). GH replacement in patients on glucocorticoid therapy may unmask previously compensated cortisol deficiency. Thyroid function should be monitored as GH can increase T4-to-T3 conversion [17][18].

15. Related Peptides

See also: HGH Fragment 176-191, IGF-1 LR3, IGF-1 DES, MGF (Mechano Growth Factor), CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren), AOD-9604

16. References

1. [1] Li CH, Dixon JS. (1971). Human pituitary growth hormone. 32. The primary structure of the hormone: revision. Arch Biochem Biophys. PubMed
2. [2] de Vos AM, Ultsch M, Kossiakoff AA. (1992). Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. DOI PubMed
3. [3] Argetsinger LS, Campbell GS, Yang X, et al. (1993). Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. DOI PubMed
4. [4] Herrington J, Smit LS, Schwartz J, Carter-Su C. (2000). The role of STAT proteins in growth hormone signaling. Oncogene. DOI PubMed
5. [5] Goeddel DV, Heyneker HL, Hozumi T, et al. (1979). Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. DOI PubMed
6. [6] GH Research Society. (2000). Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence. J Clin Endocrinol Metab. PubMed
7. [7] Wit JM, Rekers-Mombarg LT, Cutler GB, et al. (2005). Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr. PubMed
8. [8] Davenport ML, Crowe BJ, Travers SH, et al. (2007). Growth hormone treatment of early growth failure in toddlers with Turner syndrome. J Clin Endocrinol Metab. PubMed
9. [9] Ho KK; 2007 GH Deficiency Consensus Workshop Participants. (2007). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II. Eur J Endocrinol. PubMed
10. [10] Liu H, Bravata DM, Olkin I, et al. (2007). Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. PubMed
11. [11] Rubeck KZ, Bertelsen S, Lindberg U, et al. (2009). Effects of growth hormone administration on muscle strength in men over 50 years old (meta-analysis). J Clin Endocrinol Metab. PubMed
12. [12] Swerdlow AJ, Cooke R, Beckers D, et al. (2017). Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study. J Clin Endocrinol Metab. DOI PubMed
13. [13] Carel JC, Butler G. (2010). Safety of recombinant human growth hormone. Endocr Dev. PubMed
14. [14] Boguszewski MCS, Boguszewski CL, Engstrom BE, et al. (2021). Long-term safety of growth hormone replacement therapy. Growth Horm IGF Res. PubMed
15. [15] Holt RI, Sonksen PH. (2008). Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol. DOI PubMed
16. [16] Baumann GP. (2012). Growth hormone doping in sports: a critical review of use and detection strategies. Endocr Rev. DOI PubMed
17. [17] Grimberg A, DiVall SA, Engel C, et al. (2016). Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents. Horm Res Paediatr. DOI PubMed
18. [18] Molitch ME, Clemmons DR, Malozowski S, et al. (2011). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. DOI PubMed
19. [19] Deal CL, Tony M, Hoybye C, et al. (2013). Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. PubMed
20. [20] Miller BS, Velazquez E, Yuen KCJ. (2020). Long-acting growth hormone preparations -- current status and future considerations. J Clin Endocrinol Metab. PubMed